Compile Data Set for Download or QSAR
maximum 50k data
Found 158 Enz. Inhib. hit(s) with all data for entry = 2377
TargetCathepsin K(Homo sapiens (Human))
Merck Frosst Centre For Therapeutic Research

LigandPNGBDBM19856((2R)-N-(cyanomethyl)-4-methyl-2-{3-[4-(piperazin-1...)
Affinity DataIC50:  3nMpH: 5.5 T: 2°CAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCathepsin K(Homo sapiens (Human))
Merck Frosst Centre For Therapeutic Research

LigandPNGBDBM19885((2R)-N-(cyanomethyl)-4-methyl-2-{3-[4-(4-methylpip...)
Affinity DataIC50:  6nMpH: 5.5 T: 2°CAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCathepsin K(Homo sapiens (Human))
Merck Frosst Centre For Therapeutic Research

LigandPNGBDBM19893((2R)-N-(cyanomethyl)-2-(3-{4-[4-(2-hydroxy-2-methy...)
Affinity DataIC50:  6nMAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCathepsin K(Homo sapiens (Human))
Merck Frosst Centre For Therapeutic Research

LigandPNGBDBM19880((2R)-N-(cyanomethyl)-2-[3-(1H-indol-5-yl)phenyl]-4...)
Affinity DataIC50:  8nMpH: 5.5 T: 2°CAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCathepsin K(Homo sapiens (Human))
Merck Frosst Centre For Therapeutic Research

LigandPNGBDBM19884(N-(cyanomethyl)-4-methyl-2-{3-[4-(4-methylpiperazi...)
Affinity DataIC50:  8nMpH: 5.5 T: 2°CAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCathepsin K(Homo sapiens (Human))
Merck Frosst Centre For Therapeutic Research

LigandPNGBDBM19883(N-(cyanomethyl)-4-methyl-2-{3-[4-(piperazin-1-yl)p...)
Affinity DataIC50:  9nMpH: 5.5 T: 2°CAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCathepsin K(Homo sapiens (Human))
Merck Frosst Centre For Therapeutic Research

LigandPNGBDBM19890((2R)-N-(cyanomethyl)-4-methyl-2-(3-{4-[4-(2-oxopro...)
Affinity DataIC50:  10nMAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCathepsin K(Homo sapiens (Human))
Merck Frosst Centre For Therapeutic Research

LigandPNGBDBM19892((2R)-N-(cyanomethyl)-2-(3-{4-[4-(2-hydroxyethyl)pi...)
Affinity DataIC50:  12nMAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCathepsin K(Homo sapiens (Human))
Merck Frosst Centre For Therapeutic Research

LigandPNGBDBM19894((2R)-2-(3-{4-[4-(2-amino-2-methylpropyl)piperazin-...)
Affinity DataIC50:  16nMAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCathepsin K(Homo sapiens (Human))
Merck Frosst Centre For Therapeutic Research

LigandPNGBDBM19887(N-(cyanomethyl)-4-methyl-2-{3-[4-(piperidin-4-yl)p...)
Affinity DataIC50:  18nMpH: 5.5 T: 2°CAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCathepsin K(Homo sapiens (Human))
Merck Frosst Centre For Therapeutic Research

LigandPNGBDBM19891((2R)-2-{3-[4-(4-tert-butylpiperazin-1-yl)phenyl]ph...)
Affinity DataIC50:  20nMAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCathepsin K(Homo sapiens (Human))
Merck Frosst Centre For Therapeutic Research

LigandPNGBDBM19888((2R)-2-[3-(4-{1-azabicyclo[2.2.2]octan-4-yl}phenyl...)
Affinity DataIC50:  37nMpH: 5.5 T: 2°CAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCathepsin S(Homo sapiens (Human))
Merck Frosst Centre For Therapeutic Research

LigandPNGBDBM19861((2S)-N-(cyanomethyl)-4-methyl-2-(phenylformamido)p...)
Affinity DataIC50:  41nMAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetProcathepsin L(Homo sapiens (Human))
Merck Frosst Centre For Therapeutic Research

LigandPNGBDBM19861((2S)-N-(cyanomethyl)-4-methyl-2-(phenylformamido)p...)
Affinity DataIC50:  42nMAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCathepsin K(Homo sapiens (Human))
Merck Frosst Centre For Therapeutic Research

LigandPNGBDBM19899((4S)-N-(cyanomethyl)-4-methyl-2-{3-[4-(4-methylpip...)
Affinity DataIC50:  51nMAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCathepsin K(Homo sapiens (Human))
Merck Frosst Centre For Therapeutic Research

LigandPNGBDBM19861((2S)-N-(cyanomethyl)-4-methyl-2-(phenylformamido)p...)
Affinity DataIC50:  51nMpH: 5.5 T: 2°CAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCathepsin K(Homo sapiens (Human))
Merck Frosst Centre For Therapeutic Research

LigandPNGBDBM19878(N-(cyanomethyl)-2-[3-(1H-indol-5-yl)phenyl]-4-meth...)
Affinity DataIC50:  52nMpH: 5.5 T: 2°CAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCathepsin K(Homo sapiens (Human))
Merck Frosst Centre For Therapeutic Research

LigandPNGBDBM19862(N-(cyanomethyl)-4-methyl-2-(3-phenylphenyl)pentana...)
Affinity DataIC50:  56nMpH: 5.5 T: 2°CAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCathepsin K(Homo sapiens (Human))
Merck Frosst Centre For Therapeutic Research

LigandPNGBDBM19886(N-(cyanomethyl)-4-methyl-2-{3-[4-(1,2,3,6-tetrahyd...)
Affinity DataIC50:  57nMpH: 5.5 T: 2°CAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCathepsin K(Homo sapiens (Human))
Merck Frosst Centre For Therapeutic Research

LigandPNGBDBM19882(N-(cyanomethyl)-4-methyl-2-{3-[2-(piperazin-1-yl)p...)
Affinity DataIC50:  58nMpH: 5.5 T: 2°CAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCathepsin K(Homo sapiens (Human))
Merck Frosst Centre For Therapeutic Research

LigandPNGBDBM19900(N-(cyanomethyl)-3-cyclobutyl-2-{3-[4-(4-methylpipe...)
Affinity DataIC50:  62nMAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCathepsin K(Homo sapiens (Human))
Merck Frosst Centre For Therapeutic Research

LigandPNGBDBM19898(N-(cyanomethyl)-3-cyclopropyl-2-{3-[4-(4-methylpip...)
Affinity DataIC50:  65nMAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCathepsin K(Homo sapiens (Human))
Merck Frosst Centre For Therapeutic Research

LigandPNGBDBM19879((2S)-N-(cyanomethyl)-2-[3-(1H-indol-5-yl)phenyl]-4...)
Affinity DataIC50:  79nMpH: 5.5 T: 2°CAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCathepsin K(Homo sapiens (Human))
Merck Frosst Centre For Therapeutic Research

LigandPNGBDBM19897(N-(cyanomethyl)-2-{3-[4-(4-methylpiperazin-1-yl)ph...)
Affinity DataIC50:  87nMAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCathepsin K(Homo sapiens (Human))
Merck Frosst Centre For Therapeutic Research

LigandPNGBDBM19876((2R)-N-(Cyanomethyl)-4-methyl-2-[4 -(4-pyridinyl)[...)
Affinity DataIC50:  97nMpH: 5.5 T: 2°CAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetProcathepsin L(Homo sapiens (Human))
Merck Frosst Centre For Therapeutic Research

LigandPNGBDBM19892((2R)-N-(cyanomethyl)-2-(3-{4-[4-(2-hydroxyethyl)pi...)
Affinity DataIC50:  140nMAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCathepsin K(Homo sapiens (Human))
Merck Frosst Centre For Therapeutic Research

LigandPNGBDBM19864(N-(cyanomethyl)-4-methyl-2-(5-phenylpyridin-3-yl)p...)
Affinity DataIC50:  142nMpH: 5.5 T: 2°CAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCathepsin K(Homo sapiens (Human))
Merck Frosst Centre For Therapeutic Research

LigandPNGBDBM19875(N-(cyanomethyl)-4-methyl-2-[3-(pyridin-4-yl)phenyl...)
Affinity DataIC50:  150nMpH: 5.5 T: 2°CAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCathepsin K(Homo sapiens (Human))
Merck Frosst Centre For Therapeutic Research

LigandPNGBDBM19881(N-(cyanomethyl)-4-methyl-2-{3-[3-(piperazin-1-yl)p...)
Affinity DataIC50:  216nMpH: 5.5 T: 2°CAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCathepsin K(Homo sapiens (Human))
Merck Frosst Centre For Therapeutic Research

LigandPNGBDBM19877(N-(cyanomethyl)-2-[3-(1H-indol-6-yl)phenyl]-4-meth...)
Affinity DataIC50:  291nMpH: 5.5 T: 2°CAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetProcathepsin L(Homo sapiens (Human))
Merck Frosst Centre For Therapeutic Research

LigandPNGBDBM19882(N-(cyanomethyl)-4-methyl-2-{3-[2-(piperazin-1-yl)p...)
Affinity DataIC50:  338nMAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCathepsin B(Homo sapiens (Human))
Merck Frosst Centre For Therapeutic Research

LigandPNGBDBM19891((2R)-2-{3-[4-(4-tert-butylpiperazin-1-yl)phenyl]ph...)
Affinity DataIC50:  379nMAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCathepsin K(Homo sapiens (Human))
Merck Frosst Centre For Therapeutic Research

LigandPNGBDBM19874(N-(cyanomethyl)-4-methyl-2-[3-(pyridin-3-yl)phenyl...)
Affinity DataIC50:  488nMpH: 5.5 T: 2°CAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetProcathepsin L(Homo sapiens (Human))
Merck Frosst Centre For Therapeutic Research

LigandPNGBDBM19862(N-(cyanomethyl)-4-methyl-2-(3-phenylphenyl)pentana...)
Affinity DataIC50:  498nMAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCathepsin S(Homo sapiens (Human))
Merck Frosst Centre For Therapeutic Research

LigandPNGBDBM19882(N-(cyanomethyl)-4-methyl-2-{3-[2-(piperazin-1-yl)p...)
Affinity DataIC50:  521nMAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCathepsin B(Homo sapiens (Human))
Merck Frosst Centre For Therapeutic Research

LigandPNGBDBM19890((2R)-N-(cyanomethyl)-4-methyl-2-(3-{4-[4-(2-oxopro...)
Affinity DataIC50:  550nMAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCathepsin B(Homo sapiens (Human))
Merck Frosst Centre For Therapeutic Research

LigandPNGBDBM19886(N-(cyanomethyl)-4-methyl-2-{3-[4-(1,2,3,6-tetrahyd...)
Affinity DataIC50:  554nMAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCathepsin S(Homo sapiens (Human))
Merck Frosst Centre For Therapeutic Research

LigandPNGBDBM19892((2R)-N-(cyanomethyl)-2-(3-{4-[4-(2-hydroxyethyl)pi...)
Affinity DataIC50:  609nMAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCathepsin K(Homo sapiens (Human))
Merck Frosst Centre For Therapeutic Research

LigandPNGBDBM19871(N-(cyanomethyl)-4-methyl-2-{3-[2-(morpholin-4-yl)p...)
Affinity DataIC50:  614nMpH: 5.5 T: 2°CAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCathepsin K(Homo sapiens (Human))
Merck Frosst Centre For Therapeutic Research

LigandPNGBDBM19870(N-(cyanomethyl)-4-methyl-2-{3-[3-(morpholin-4-yl)p...)
Affinity DataIC50:  630nMpH: 5.5 T: 2°CAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCathepsin K(Homo sapiens (Human))
Merck Frosst Centre For Therapeutic Research

LigandPNGBDBM19869(N-(cyanomethyl)-4-methyl-2-{3-[4-(morpholin-4-yl)p...)
Affinity DataIC50:  638nMpH: 5.5 T: 2°CAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCathepsin S(Homo sapiens (Human))
Merck Frosst Centre For Therapeutic Research

LigandPNGBDBM19886(N-(cyanomethyl)-4-methyl-2-{3-[4-(1,2,3,6-tetrahyd...)
Affinity DataIC50:  652nMAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCathepsin K(Homo sapiens (Human))
Merck Frosst Centre For Therapeutic Research

LigandPNGBDBM19863(N-(cyanomethyl)-4-methyl-2-(4-phenylphenyl)pentana...)
Affinity DataIC50:  790nMpH: 5.5 T: 2°CAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCathepsin K(Homo sapiens (Human))
Merck Frosst Centre For Therapeutic Research

LigandPNGBDBM19873(N-(cyanomethyl)-4-methyl-2-[3-(pyridin-2-yl)phenyl...)
Affinity DataIC50:  803nMpH: 5.5 T: 2°CAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetProcathepsin L(Homo sapiens (Human))
Merck Frosst Centre For Therapeutic Research

LigandPNGBDBM19864(N-(cyanomethyl)-4-methyl-2-(5-phenylpyridin-3-yl)p...)
Affinity DataIC50:  825nMAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetProcathepsin L(Homo sapiens (Human))
Merck Frosst Centre For Therapeutic Research

LigandPNGBDBM19871(N-(cyanomethyl)-4-methyl-2-{3-[2-(morpholin-4-yl)p...)
Affinity DataIC50:  919nMAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCathepsin K(Homo sapiens (Human))
Merck Frosst Centre For Therapeutic Research

LigandPNGBDBM19889(Nonpeptidic Biaryl Nitrile Compound, 50 | tert-but...)
Affinity DataIC50:  922nMpH: 5.5 T: 2°CAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCathepsin S(Homo sapiens (Human))
Merck Frosst Centre For Therapeutic Research

LigandPNGBDBM19878(N-(cyanomethyl)-2-[3-(1H-indol-5-yl)phenyl]-4-meth...)
Affinity DataIC50:  922nMAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCathepsin K(Homo sapiens (Human))
Merck Frosst Centre For Therapeutic Research

LigandPNGBDBM19866(4-(3-{1-[(cyanomethyl)carbamoyl]-3-methylbutyl}phe...)
Affinity DataIC50:  1.02E+3nMpH: 5.5 T: 2°CAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCathepsin K(Homo sapiens (Human))
Merck Frosst Centre For Therapeutic Research

LigandPNGBDBM19872(N-(Cyanomethyl)-4-methyl-2-(3-pyrimidin-5-ylphenyl...)
Affinity DataIC50:  1.04E+3nMpH: 5.5 T: 2°CAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
Displayed 1 to 50 (of 158 total ) | Next | Last >>
Jump to: